- In a rural Arizona clinic, a retrospective chart review identified
150 women on either Norplant, Depo-Provera, or OCP.(1)
- 50 women in each contraceptive group were identified who
met all the study criteria. (15-30 years old, no prior contraception,
height between 62 -70 inches, weight between 100-180 lbs., no
diabetes, no thyroid disease, and greater than 12 months postpartum)
- Body weight was compared initially and at 12 months. Age,
height, and parity were also evaluated. The Depo-Provera group
had lower baseline weights. OCP group was older and had few
- Results: Mean 1 year weight gain for subjects in each of
the 3 treatment groups was: -0.93 kg (95% CI= -1.3 to 0.5) in
the OCP group, -0.81 kg (95% CI= - 1.6 to 0.1 kg) in the Norplant
group, and + 0.06 kg (95% CI= -0.4 to 0.6 kg) in the Depo-Provera
- They suggest that concerns regarding weight gain during Depo-Provera,
Norplant, and OCP therapy, specifically, among patients their
clinic may be unfounded.
- In an Ohio adolescent clinic, a prospective study examined
clinical profiles among adolescents who chose Norplant (58 adolescents),
Depo-Provera (66 adolescents), and Ortho-cept (75 adolescents).(2)
- At baseline, at 3 months, and at 6 months, patients were
interviewed regarding gynecologic history, side effects, and
satisfaction. A physical exam and weight (Body Mass Index =
weight-kg/ height (m2)) was also measured.
- The average subject was 15.5 years (range 11-20 years); 66%
were African-American and 34% Caucasian.
- Results: The mean BMI at baseline for all the treatment groups
was 24.2 +/- 5.5; the overall mean at the first follow-up visit
was 24.4 +/- 5.9 and the mean at the second follow-up visit
was 25.9 +/- 5.8.
- They concluded that there were no differences found in body
mass index among the different treatment groups at any visit
or within any group between baseline and either follow-up.